In 2020, a new combination of an anti-VEGF-A inhibitor (bevacizumab) and an anti-PD-L1 (atezolizumab) demonstrated significant efficacy and became the standard-of-care for HCC based on the results of IMbrave150 [97,103]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.